BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that the U.S. Food and Drug Administration (FDA) has approved the second drug to be offered in the recently launched BD Simplist™  line of ready-to-administer prefilled generic injectables. The second BD Simplist product to launch is Metoclopramide Injection, USP, an injectable antiemetic.

BD Rx launched its first drug – BD Simplist™ Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine – on March 27, 2013. BD Simplist prefilled injectables are designed to help improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence, reducing the potential risk of medication error.

"After a successful launch of BD Simplist prefilled injectables, we're excited to be coming out with a second drug that is commonly used by clinicians. This is just the beginning of our new line of prefilled injectable products," said Mark Sebree , President, BD Rx. "BD has a long-standing reputation for delivering high-quality, high-volume products. Our work at BD Rx is no different, as we bring that same commitment to quality and patient safety to our new work in generic drug manufacturing."

The potential for medication error exists with every injection. Clinicians perform up to 20 steps in a traditional vial and syringe injection sequence. But with BD Simplist prefilled injectables, the injection sequence is reduced to approximately 12 steps, reducing the potential risk of medication error and allowing for more focus on the patient and less on injection preparation.

The company plans to launch 20 to 30 drugs in its BD Simplist line of products during the next few years and is targeting generic injectables in doses most commonly relied on by clinicians in both the hospital and surgical center settings.

Source:

BD-Becton Dickinson

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Becton, Dickinson and Company. (2019, June 20). BD receives FDA approval for second prefilled injectable drug. News-Medical. Retrieved on December 10, 2019 from https://www.news-medical.net/news/20130424/BD-receives-FDA-approval-for-second-prefilled-injectable-drug.aspx.

  • MLA

    Becton, Dickinson and Company. "BD receives FDA approval for second prefilled injectable drug". News-Medical. 10 December 2019. <https://www.news-medical.net/news/20130424/BD-receives-FDA-approval-for-second-prefilled-injectable-drug.aspx>.

  • Chicago

    Becton, Dickinson and Company. "BD receives FDA approval for second prefilled injectable drug". News-Medical. https://www.news-medical.net/news/20130424/BD-receives-FDA-approval-for-second-prefilled-injectable-drug.aspx. (accessed December 10, 2019).

  • Harvard

    Becton, Dickinson and Company. 2019. BD receives FDA approval for second prefilled injectable drug. News-Medical, viewed 10 December 2019, https://www.news-medical.net/news/20130424/BD-receives-FDA-approval-for-second-prefilled-injectable-drug.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New BD Vacutainer Barricor Plasma Blood Collection tube earns CE mark approval